Sleep apnoea: tirzepatide reduced night-time breathing pauses

Two phase 3 trials in adults with moderate-to-severe obstructive sleep apnoea and obesity.

SURMOUNT-OSA combined two phase 3, double-blind trials in adults with moderate-to-severe obstructive sleep apnoea and obesity. The main measure was the apnoea–hypopnoea index: how many breathing pauses occur per hour of sleep.

After 52 weeks, tirzepatide reduced that index more than placebo in both trials. An editorial in the same journal described it as the start of a new era in sleep-apnoea treatment.

In three points

Two phase 3 human trials, 52 weeks
Fewer breathing pauses per hour of sleep
Improvement also linked to weight loss

Compounds mentioned

Tirzepatide

Original source: Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
PubMed · New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.